P714: Efficacy and safety of infliximab retreatment in luminal Crohn’s disease: a multi-centre, prospective, observational cohort (REGAIN) study
ECCO '19 Copenhagen
2019
P715: Real-world tofacitinib effectiveness and safety in patients with refractory ulcerative colitis
ECCO '19 Copenhagen
2019
P716: The use of tacrolimus in patients with ulcerative colitis resistant to standard medical therapy
ECCO '19 Copenhagen
2019
P717: The use of combination biologic therapy in inflammatory bowel disease: A single tertiary-centre experience
ECCO '19 Copenhagen
2019
P718: Risk of tuberculosis in patients with inflammatory bowel disease receiving biologics using two interferon-γ release assays as monitoring
ECCO '19 Copenhagen
2019
P719: Update of a network meta-analysis of efficacy and safety of different intravenous iron compounds in patients with IBD and anaemia
ECCO '19 Copenhagen
2019
P720: Efficacy of exclusive enteral nutrition for induction and partial enteral nutrition for maintenance of remission in newly diagnosed paediatric and adolescent Crohn’s disease
ECCO '19 Copenhagen
2019
P721: Effect of thalidomide on clinical remission in adult with refractory crohn disease, a multicentre, randomised, double-blind clinical trial
ECCO '19 Copenhagen
2019
P722: Results of the STAR study: management of ulcerative colitis in private practice in france, in the first years following diagnosis
ECCO '19 Copenhagen
2019
P723: Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with iron isomaltoside or ferric carboxymaltose: results of a prospective cluster randomised cohort study
ECCO '19 Copenhagen
2019
P724: Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data
ECCO '19 Copenhagen
2019
P725: A prospective study of planned switch from Infliximab originator remicade to biosimilar inflectra: a multi-centre Irish experience
ECCO '19 Copenhagen
2019
P726: Trough levels of infliximab better correlate with combined mucosal and transmural healing than clinical remission in Korean patients with Crohn’s disease on infliximab maintenance therapy
ECCO '19 Copenhagen
2019
P727: Quality of life and disease activity in children and adolescents with inflammatory bowel disease
ECCO '19 Copenhagen
2019
P728: Effectiveness and quality of life (QoL) of Ustekinumab (UST) therapy in a Real-world Setting in Germany – First Results of the RUN-CD Study
ECCO '19 Copenhagen
2019
P729: Faecal calprotectin and faecal immunochemical test have different values depending on mucosal status in patients with ulcerative colitis
ECCO '19 Copenhagen
2019
P731: Characteristics and follow-up on body composition, physical activity and quality of life in paediatric patients with inflammatory bowel disease
ECCO '19 Copenhagen
2019